Clinical trial
A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols
NCT00948064 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 8, 2009
- Completion date
- August 3, 2017
- Enrollment
- 110 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.